ARGX-117-2002

Neurology & Rehabilitation Medicine

This is a phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and efficacy of 2 dose regimens of ARGX-117 versus placebo, in participants with MMN previously stabilized with IVIg (intravenous immunoglobulin).

Sponsor(s)

argenx

Principal Investigator(s)

Dr. Mohammad Abu-Rub

Request Information

First Name

Last Name

Email Address

Confirm email

Phone Number

Address

Address 2

City/Town

State/Province

ZIP/Postal Code

Comments / Questions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.